Jacobs Levy Equity Management Inc. Has $9.25 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Jacobs Levy Equity Management Inc. lifted its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTLFree Report) by 112.0% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 547,403 shares of the company’s stock after buying an additional 289,252 shares during the period. Jacobs Levy Equity Management Inc. owned about 2.03% of Castle Biosciences worth $9,246,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Deerfield Management Company L.P. Series C acquired a new position in shares of Castle Biosciences during the 3rd quarter worth $15,988,000. Schonfeld Strategic Advisors LLC increased its holdings in Castle Biosciences by 294.4% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 148,030 shares of the company’s stock worth $2,500,000 after purchasing an additional 110,500 shares in the last quarter. Millrace Asset Group Inc. acquired a new position in Castle Biosciences in the 3rd quarter worth about $1,306,000. Portolan Capital Management LLC increased its holdings in Castle Biosciences by 68.1% in the 2nd quarter. Portolan Capital Management LLC now owns 431,474 shares of the company’s stock worth $5,920,000 after purchasing an additional 174,825 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in Castle Biosciences by 9.0% in the 3rd quarter. Principal Financial Group Inc. now owns 1,482,170 shares of the company’s stock worth $25,034,000 after purchasing an additional 122,169 shares in the last quarter. Institutional investors and hedge funds own 85.75% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on CSTL. KeyCorp upped their target price on Castle Biosciences from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Friday, March 1st. Scotiabank upped their target price on Castle Biosciences from $33.00 to $37.00 and gave the stock a “sector outperform” rating in a report on Friday, March 1st. Finally, Guggenheim started coverage on Castle Biosciences in a research note on Thursday, December 14th. They issued a “buy” rating and a $25.00 price target for the company.

View Our Latest Report on CSTL

Castle Biosciences Price Performance

Shares of CSTL stock opened at $19.96 on Wednesday. The stock has a 50-day moving average of $22.13 and a 200-day moving average of $19.37. Castle Biosciences, Inc. has a 1-year low of $9.26 and a 1-year high of $26.70.

Insider Activity

In related news, Director Daniel Bradbury sold 18,223 shares of the company’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $20.40, for a total transaction of $371,749.20. Following the sale, the director now owns 43,574 shares in the company, valued at approximately $888,909.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Daniel Bradbury sold 18,223 shares of the company’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $20.40, for a total transaction of $371,749.20. Following the sale, the director now owns 43,574 shares in the company, valued at approximately $888,909.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Derek J. Maetzold sold 2,372 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $20.77, for a total value of $49,266.44. Following the sale, the insider now owns 72,101 shares in the company, valued at approximately $1,497,537.77. The disclosure for this sale can be found here. Over the last quarter, insiders sold 75,402 shares of company stock valued at $1,581,299. Company insiders own 7.70% of the company’s stock.

About Castle Biosciences

(Free Report)

Castle Biosciences, Inc, a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.

Featured Articles

Institutional Ownership by Quarter for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.